

TABLE OF CONTENTS

Book 1

Preface	i
Editorial Board	ii
Book 1 Panel	iii
Continuing Education and Program Evaluation Instructions	viii
Roles of ACCP and BPS	xi

Cardiology I

ACUTE CORONARY SYNDROMES

Learning Objectives	1
Introduction	1
Epidemiology of Acute Myocardial Infarction	1
Differentiating Acute Coronary Syndromes	1
Economic Costs of ACS	3
Pathophysiology	3
Spectrum From Stable Angina To AMI	3
Pathology	3
Complications	4
Clinical Presentation and Diagnosis	4
Electrocardiogram	4
Biochemical Markers	4
Risk Stratification	5
ST-segment Elevation ACS	6
Non-ST-segment Elevation ACS	6
Treatment Goals	8
Quality Patient Care	8
Pharmacological Therapy for STE ACS	9
General Treatment Approach (Algorithm/Guidelines)	9

Aspirin, Intravenous Nitroglycerin, and β-Blockers	9
Thrombolysis	10
Unfractionated Heparin Versus Enoxaparin	17
Angiotensin-converting Enzyme Inhibitors	17
Early Initiation of Statin Therapy	18
Important Ongoing Clinical Trials that may Shape Clinical Practice	19
Pharmacological Therapy For NSTEMI ACS	19
General Treatment Approach (Algorithm/Guidelines)	19
Aspirin Alone Versus Aspirin plus Clopidogrel ..	21
Unfractionated Heparin Versus Low-molecular-weight Heparin	22
Glycoprotein IIb/IIIa Receptor Blockers	23
Important Ongoing Clinical Trials that may Shape Clinical Practice	24
Percutaneous Coronary Intervention of STE ACS ..	24
Primary PCI Versus Thrombolysis	24
Adjunctive GP IIb/IIIa Receptor Blockers	26
Rescue PCI and Rescue Thrombolysis	26
Percutaneous Coronary Intervention During Hospitalization of AMI	27
Important Ongoing Trials that may Shape Clinical Practice	27
Percutaneous Coronary Intervention of NSTEMI ACS ..	27
Medical Stabilization Versus Early PCI	27
Enoxaparin	28
Important Ongoing Trials that may Shape Clinical Practice	28
Patient-Specific Treatment Plan	28
Timing of β-Blocker and ACE Inhibitor Administration in Patients with ACS Presenting with Acute Heart Failure	29
Patient Education	31
Quality Improvement	31
ST-segment Elevation ACS	31
Non-ST-segment Elevation ACS	32
Conclusions	33

Annotated Bibliography	33
Self-Assessment Questions	35

ACUTE MANAGEMENT OF ARRHYTHMIA

Learning Objectives	41
Introduction	41
Supraventricular Arrhythmias	42
Pathophysiology	42
Definition of Different Types of Supraventricular Arrhythmias	42
Sinus Bradycardia	42
Asystole	42
Pulseless Electrical Activity	42
Atrial Fibrillation	43
Atrial Flutter	43
Paroxysmal Supraventricular Tachycardia	43
Epidemiology and Prognosis	44
Diagnosis	44
Goals of Treatment	44
Quality Pharmaceutical Care	44
Management of Sinus Bradycardia	44
Management of Asystole	47
Management of PEA	47
Management of AF/Aflu Rate Control	47
Restoration of Normal Sinus Rhythm	48
Prevention of Thromboembolic Events	50
Postsurgical Atrial Fibrillation	51
Management of PSVT	52
Ventricular Tachyarrhythmias	52
Pathophysiology	52
Definition of Different Types of Ventricular Tachyarrhythmia	52
Nonsustained VT	53
Sustained VT	53
Ventricular Fibrillation/Pulseless VT	54
Sudden Cardiac Death	54
Epidemiology and Prognosis	54
Diagnosis	55
Goals of Treatment	55
Quality Pharmaceutical Care	55
Management of Wide Complex Tachycardia of Unknown Original	55
Management of Asymptomatic Nonsustained VT	55
Management of Sustained VT and Symptomatic Nonsustained VT	56
Sustained VT in Patients with Preserved Left Ventricular Function	57
Sustained VT in Patients with Left Ventricular Dysfunction	57
Torsades de Pointes and Other Drug-induced VTs	58
Management of VF/Pulseless VT	58
Non-pharmacological Management of Ventricular Arrhythmias	59
Automated External Defibrillator and Public Access Defibrillation	59
Annotated Bibliography	60

Self-Assessment Questions	63
--	-----------

DECOMPENSATED AND ADVANCED HEART FAILURE

Learning Objectives	67
Introduction	67
Pathophysiology	68
Cardiorenal and Circulatory Model	68
Neurohormonal Model	69
Renin-angiotensin-aldosterone System	69
Sympathetic Nervous System	70
Endothelial Hormones	71
Arginine Vasopressin	71
Atrial and B-type Natriuretic Peptides	71
Neutral Endopeptidase	72
Cytokines	72
Ventricular Remodeling	72
Systolic and Diastolic Dysfunction	73
Decompensated Heart Failure	73
Clinical Presentation	73
Warm and Wet	73
Cool and Dry	74
Cool and Wet	74
Precipitating Factors	74
Cardiovascular Etiologies	74
Metabolic Derangements	75
Drugs	75
Treatment Adherence	75
Diagnostic Tools	75
Physical Examination	75
Noninvasive Testing	75
Laboratory Assessment	76
Routine Laboratory Testing	76
B-type Natriuretic Peptide	76
Hemodynamic Monitoring	76
Therapeutic Goals	76
Pharmacological Therapy	77
Therapeutic Agents	77
Diuretics	77
Diuretic Resistance	77
Vasodilators	78
Nitroprusside	78
Nitrates	79
Nesiritide	79
Inotropes	81
β -Adrenergic Receptor Agonists	81
Milrinone	82
Vasopressors	83
Investigational Agents	83
Levosimendan	83
Tezosentan	84
Management of Decompensation Episodes	84
Warm and Wet	85
Cool and Dry	85
Cool and Wet	86
Cardiogenic Shock	87

Monitoring	88
Chronic Advanced Heart Failure	88
Oral Therapy	88
Avoiding Future Decompensation Episodes	89
Long-term Inotropic Therapy	89
Non-Pharmacological Therapy	90
Intra-aortic Balloon Counterpulsation	90
Cardiac Resynchronization	91
Alternative Surgical Procedures	92
Ventricular Assist Devices	92
Transplantation	94
Role of the Pharmacist	95
Core Measures for Quality in Heart Failure	
Hospitalization	95
Other Health System Roles	96
Conclusion	97
Annotated Bibliography	97
Self-Assessment Questions	99

Cardiology II

PREVENTION OF CARDIOVASCULAR DISEASE

Learning Objectives	107
Introduction	107
Epidemiology	107
Pathogenesis	109
Modifiable Cardiovascular Risk Factors	110
Trends in Established Risk Factors	110
Hypertension	110
Smoking	111
Dyslipidemia	112
Diabetes	112
Emerging Risk Factors	113
C-Reactive Protein	113
Cytokines	113
Fibrinogen	113
Infection	114
Metabolic Syndrome	114
Homocysteine	115
Cardiovascular Prevention Strategies	115
Prevention and Risk Assessment	115
Issues Surrounding the Effectiveness of Preventive Strategies	116
Barriers and Challenges to Cardioprotection	117
Pharmacological Therapy and Other Strategies for	
Cardioprotection	117
Antithrombotic Agents	117
Aspirin	117
Other Nonsteroidal Anti-inflammatory Drugs	118
Clopidogrel	118
Neurohormonal Blockade	119
Statins	119
Vitamin Supplementation	120
Hormone Therapy	121
Smoking Cessation	121

Physical Activity, Diet, and Weight Management	122
Conclusion	123
Annotated Bibliography	123
Self-Assessment Questions	125

MANAGEMENT OF HYPERTENSION

Learning Objectives	129
Introduction	129
Poor Blood Pressure Control	129
Pathophysiology	131
Definitions and Classification	131
Etiology	132
Clinical Characteristics	134
Diagnosis	135
Epidemiology	135
Prognosis	136
Quality Pharmaceutical Care	136
Historical Database and the Patient Interview	136
Pharmacotherapy	137
New Information from Recent Guidelines	138
Diuretics	139
β -Blockers	141
Angiotensin-converting Enzyme Inhibitors	142
Angiotensin II Receptor Antagonists	143
Calcium Channel Blockers	143
α -Blockers	144
Aldosterone Antagonists	145
Vasopeptidase Inhibitors	146
Potentially Useful Combinations	147
Special Populations	147
Diabetes Mellitus	147
Patients with Renal Insufficiency	148
Assessment and Treatment Plan	148
Titration, Monitoring, and Follow-up Visits	149
Patient Access to Care	150
Patient Satisfaction	150
Hypertensive Urgencies and Emergencies	152
Therapeutic Strategies and Guidelines	152
Lifestyle Modification	152
Pharmacological Measures	153
Efficiency	154
Efficacy	154
Effectiveness	154
Common Errors and Reasons for Lack of Treatment Effectiveness	155
Monitoring Individual Patients	155
Population Monitoring	156
Administration	157
Support Systems for the Drug Use Process	157
Documentation the Pharmacist Should Perform	157
Patient Education	157
Quality Improvement	158
Summary	158
Annotated Bibliography	158
Self-Assessment Questions	161

DYSLIPIDEMIAS	
Learning Objectives	165
Introduction	165
Dyslipidemia and Atherosclerosis	165
Dyslipidemia	165
Definitions of Dyslipidemia Types	165
Etiology	166
Atherosclerotic Plaque Formation and Disruption	167
Plaque Formation	167
Plaque Disruption	167
Impact of Lipid-lowering Therapy	167
Regression or Lack of Progression of Lesions	167
Endothelial Function and Dysfunction	167
Coronary Artery Disease Risk Status	167
Method of Risk Assessment	167
Initial Risk Assessment	167
Counting Risk Factors	169
Framingham Risk Score Estimation	169
Nonlipid Markers of CHD Risk	170
C-Reactive Protein	170
Other Markers of CHD Risk	170
Secondary Targets of Therapy	170
High-density Lipoprotein Cholesterol	170
Triglycerides	171
Non-HDL Cholesterol	171
Metabolic Syndrome	171
Homocysteine	171
Treatment	172
Therapeutic Lifestyle Changes	172
Nonlipid Risk Factor Modification	172
Dietary Modification	172
Impact of Therapeutic Lifestyle Change on CHD Risk	173
Pharmacotherapy	173
Hydroxymethyl Glutaryl Coenzyme A RIs	173
Lipid Alterations	173
Landmark Trials	173
Pleiotropic Effects	175
Muscle Safety	176
Liver Safety	177
Bile Acid Sequestrants	178
Ezetimibe	179
Fibric Acid Derivatives	179
Niacin	180
Nonprescription Therapy	181
Alcohol	181
Omega-3 Fatty Acids	181
Plant Sterols/Stanoles	182
Psyllium	182
Antioxidant Vitamin Therapy	182
Garlic	182
Red Yeast Rice	182
Tocotrienols	183
Guggulipid	183
Soy Protein	183
Non-pharmacological Management of Hyperlipidemia	183
The Pharmacist's Role in Lipid Management	183
Conclusion	185
Annotated Bibliography	185
Self-Assessment Questions	187
CHRONIC ARRHYTHMIA MANAGEMENT	
Learning Objectives	191
Introduction	191
Atrial Fibrillation	192
Pathophysiology	192
Definitions	193
Etiologies	193
Clinical Characteristics	194
Diagnosis	194
Epidemiology	195
Prognosis	195
Therapeutic Goals/Outcomes	195
Quality Pharmaceutical Care	196
Pharmacological Therapy	196
Chronic Ventricular Rate Control	196
β -Blockers	196
Nondihydropyridine Calcium Channel Blockers	196
Digoxin	197
Combination Therapy	197
Restoration of Sinus Rhythm	197
Flecainide	198
Propafenone	198
Oral Amiodarone	199
Dofetilide	199
Common Misconceptions	200
Maintenance of Sinus Rhythm	201
Class Ic Antiarrhythmics	201
Class III Antiarrhythmics	201
Rate Versus Rhythm Control for Managing Chronic AF	202
Preventing Thromboembolic Events	205
Non-pharmacological Therapy	205
Treatment Plan	207
Ventricular Rate Control	207
Restoration of Sinus Rhythm	209
Maintaining Sinus Rhythm	209
Preventing Thromboembolism	209
Rate Versus Rhythm Control for Chronic Management of AF	210
Pharmacoeconomics and Quality of Life	212
Monitoring	213
Patient Education	215
Ventricular Arrhythmias	215
Definitions	215
Premature Ventricular Contractions	215
Ventricular Tachycardia	215
Ventricular Fibrillation	215
Sudden Cardiac Death	215

Etiologies and Risk Factors	.216
Clinical Characteristics	.216
Diagnosis	.216
Epidemiology	.217
Prognosis	.217
Therapeutic Goals and Outcomes	.217
Quality Pharmaceutical Care	.217
Pharmacological Therapy	.217
Chronic Suppression of Symptomatic PVCs	.217
Primary Prevention of SCD in Patients with NSVT	.217
Primary Prevention of SCD in Other High-risk Patients	.219
Secondary Prevention of SCD	.220
Non-pharmacological Therapy	.221
Treatment Plan	.221
Chronic Suppression of Symptomatic PVCs	.221
Primary Prevention of SCD in Patients with NSVT or Other High-risk Factors	.221
Secondary Prevention of SCD	.223
Pharmacoeconomics and Quality of Life	.223
Monitoring	.224
Patient Education	.224
Preventing Drug-induced Ventricular Tachyarrhythmias	.224
Etiologies and Risk Factors	.225
Preventing Drug-induced Ventricular Tachyarrhythmias	.225
Conclusion	.226
Annotated Bibliography	.226
Self-Assessment Questions	.229

Cardiology III

MANAGEMENT OF CHRONIC STABLE ANGINA

Learning Objectives	.237
Introduction	.237
Magnitude of the Problem	.237
Pathophysiology	.237
Clinical Evaluation of the Patient	.239
Clinical Presentation	.239
Physical Findings	.240
Diagnostic Tests	.240
Electrocardiogram	.240
Exercise Stress Testing	.240
Coronary Angiography	.242
Probability of Disease Estimates	.244
Risk Stratification	.245
Pharmacological Therapy of Chronic Stable Angina	.245
Goals of Therapy	.245
Practice Guidelines	.245
Nitrates	.246
Nitrate Tolerance	.246
β -Blockers	.247
Calcium Channel Blockers	.248

Safety Concerns with CCB Use	.248
Revascularization	.249
Coronary Artery Bypass Graft Surgery Versus Medical Management	.249
Coronary Artery Bypass Graft Surgery Versus PCI	.251
PCI Versus Medical Therapy	.252
Complications of PCI	.253
Transmyocardial Laser Revascularization	.255
Therapeutic Approach to Managing Chronic Stable Angina	.255
Lifestyle Modifications	.255
Acute Nitrates	.257
Antithrombotic Therapy	.257
Aspirin	.257
Adenosine Diphosphate Inhibitors	.257
Other Agents	.257
β -Blockers	.258
Calcium Channel Blockers	.259
Chronic Nitrates	.259
Lipid-lowering Therapy	.259
Angiotensin-converting Enzyme Inhibitors	.260
Nutritional Supplementation	.260
Vitamin E	.260
Folic Acid	.261
Hormone Replacement Therapy	.262
Use of Sildenafil	.262
Areas of Investigation	.263
Antimicrobial Therapy	.263
Angiogenesis	.263
Patient Education	.264
Understanding of the Disease	.264
Medical Therapy and Lifestyle Modifications	.264
Physical Activity	.265
Contacting the Medical System	.265
Quality Improvement	.266
Conclusion	.266
Annotated Bibliography	.266
Self-Assessment Questions	.269

SECONDARY PREVENTION OF STROKE AND MYOCARDIAL INFARCTION

Learning Objectives	.275
Introduction	.275
Definitions	.275
Therapeutic Goals	.277
National Guidelines for MI and Stroke Prevention	.277
Risk Stratification for Secondary MI and Stroke Prevention	.277
Risk Factors for MI and Stroke	.277
Nonmodifiable Risk Factors	.277
Modifiable Risk Factors	.277
Dyslipidemia	.278
Hypertension	.278
Diabetes Mellitus	.279
Smoking	.279
Lifestyle Factors	.279

C-Reactive Protein	279	Assessment of Cardiac Function	301
Homocysteine	279	Echocardiography	301
Quality Patient Care	279	Nuclear Testing	301
Pharmacotherapy	279	Coronary Angiography with Ventriculography	302
Dyslipidemic Agents	279	Clinical Assessment	302
Statins	280	Evidence-based Medicine	303
Antiplatelet Therapy	281	Diuretics	303
Aspirin	281	Neurohormonal Modulators	304
Ticlopidine	281	Angiotensin-converting Enzyme Inhibitors	304
Clopidogrel	281	Alternatives to ACE Inhibitors	306
Dipyridamole	281	β -Blockers	307
Combination Antiplatelet Therapy	282	Aldosterone Antagonists	309
Antithrombotic Therapy	283	Digoxin	310
Warfarin	283	Anticoagulants	310
Combination Therapy (Aspirin plus Warfarin)	283	Calcium Channel Blockers	310
Low-intensity Warfarin	283	Non-pharmacological Therapy	311
High-intensity Warfarin	284	Implantable Cardiac Defibrillators and Biventricular	
Antihypertensive Therapy	284	Pacing	311
Angiotensin-converting Enzyme Inhibitors	285	Patient Education	311
Angiotensin Receptor Blockers	285	Depression	312
Hormone Replacement Therapy	285	Diastolic Dysfunction	312
Estrogen	285	Comorbidities and Concomitant Drugs	313
Selective Estrogen Receptor Modulators	286	Comorbidities	313
Other Therapies	286	Concomitant Drugs	313
Vitamin E/Antioxidants	286	Prescription Drugs	313
Omega-3 Fatty Acids	286	Over-the-counter and Alternative Drugs	313
Surgical Treatments	286	Implementation	314
Carotid Endarterectomy	286	One-on-one Provider Interactions Versus	
Carotid Stenting	286	Multidisciplinary Disease Management Clinics	314
Vaccination	287	Group Health Visits	314
Influenza Vaccine	287	Conclusion	314
E-Selectin Vaccine	287	Annotated Bibliography	315
Treatment Plan	287	Self-Assessment Questions	317
Closing the Treatment Gap	287		
Patient Factors	287		
Knowledge	287		
Compliance	287		
Physician Factors	288		
Health Care System Factors	288		
Collaboration of Care	289		
Monitoring/Documentation	289		
Quality Improvement	289		
Summary	289		
Annotated Bibliography	289		
Self-Assessment Questions	293		

CHRONIC MANAGEMENT OF HEART FAILURE

Learning Objectives	297
Introduction	297
Epidemiology	297
Etiology	298
Definitions	299
Classification	299
Prognosis and Costs	300
Brief Overview of Pathophysiology	300
Assessment	301